Nitin Jain
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Nitin Jain
Jul 23, 2024, 22:30 |
Blog
Hagop Kantarjian: The simultaneous combination of ponatinib and blinatumomab highly effective
Hagop Kantarjian shared on X: "The simultaneous combination of ponatinib and blinatumomab highly effective: MRD-negativity rate…
Jul 14, 2024, 07:11 |
Blog
Naveen Pemmaraju: Nitin Jain and Rami Komrokji kick off the US AML-ALL Focus meeting
Naveen Pemmaraju shared a post on X: . "Superb talks by Nitin Jain on Highlights…
Jul 12, 2024, 16:59 |
Insight
Naveen Pemmaraju: Two of the finest people I have ever known
Naveen Pemmaraju shared a post on X: “Just landed MD Education AML-ALL US Focus meeting…
Jul 10, 2024, 08:52 |
Blog
Nitin Jain: CML response definitions
Fadi Haddad, Assistant Professor at the Leukemia Department at the MD Anderson Cancer Center, reposted…
Jun 29, 2024, 16:57 |
Insight
MD Anderson Research Highlights: EHA 2024 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in…
Jun 22, 2024, 13:29 |
Blog
Nitin Jain: Last day for Dr Alex Bataller as Leukemia fellow
Nitin Jain shared a post on X: "Last day for Dr Alex Bataller as Leukemia fellow.…
Jun 19, 2024, 23:09 |
Blog
Wei Ying Jen: Very grateful to be standing on the shoulders of giants
Wei Ying Jen, Haematologist and Leukemia Doctor at MD Anderson Cancer Center, shared on X:…
Jun 17, 2024, 07:05 |
Societies
15 Posts You Should Not Miss From EHA 2024!
The European Hematology Association (EHA) Hybrid Congress or EHA2024 will took place in Madrid, Spain…
Jun 9, 2024, 14:56 |
Societies
ESH MICRO 2025 registration is open
The European School of Haematology (ESH) shared a post on X: “ESH MICRO 2025 registration…
May 22, 2024, 01:53 |
Insight
Nitin Jain: Looking forward to presenting phase 2 trial of frontline treatment for patients with CLL at EHA 2024
Nitin Jain, Professor of the Department of Leukemia at MD Anderson Cancer Center, shared on…
May 21, 2024, 07:10 |
Blog
Nitin Jain: Brief summary slide with some general concepts about assay depth
Nitin Jain, Professor of Medicine in the Department of Leukemia at The University of Texas MD…
May 17, 2024, 15:32 |
Blog
Nitin Jain: Looking forward to frontline Rx for patients with CLL at EHA2024
Nitin Jain, Professor of Medicine in the Department of Leukemia at The University of Texas MD…
May 2, 2024, 09:25 |
Blog
Rahul Gosain: HemeSeries with Nitin Jain
Rahul Gosain, Director of Regional Infusion Services at Wilmot Cancer Institute, shared a post on LinkedIn: "HemeSeries:…
Apr 25, 2024, 00:14 |
Blog
Anand Patel: Make sure to sign up for Heme Reports next session!
Anand Patel, Assistant Professor of hematology and oncology at UChicago Medicine, shared a post by Heme…
Mar 29, 2024, 05:47 |
Blog
Nitin Jain: Fantastic talk by Dr Hind Rafei on current status of NK cell therapy
Katy Rezvani Chief of Section of Cellular Therapy, Department of Stem Cell Transplantation and Cellular…
Mar 19, 2024, 03:44 |
Drugs
Nitin Jain: The U.S. FDA approves lisocabtagene maraleucel for adults with relapsed or refractory CLL or SLL
Nitin Jain, The Director of the Leukemia CAR-T Program at the MD Anderson Cancer Center,…
Feb 26, 2024, 19:14 |
Blog
Nitin Jain: Our trial of ponatinib VEN + mini-CVD for R/R T-ALL is now open
Nitin Jain, the Director of the Leukemia CAR-T Program at the MD Anderson Cancer Center,…
Feb 1, 2024, 22:40 |
Blog
Naveen Pemmaraju: Super spectacular India trip now completed!
Naveen Pemmaraju shared on X/Twitter: “Super spectacular India trip now completed! Many new memories & all-time…
Dec 15, 2023, 06:01 |
Blog
Othman Al-Sawaf: The primary analysis of the RT1 study just went online at Nature Medicine
Othman Al-Sawaf, haematologist and medical oncologist at the University Hospital Cologne, Cologne, Germany, shared a…
Dec 14, 2023, 16:06 |
Blog
Nitin Jain: Wonderful to celebrate India’s CD19 CAR T approval
Nitin Jain, the Director of the Leukemia CAR-T Program at the MD Anderson Cancer Center,…
Sep 18, 2023, 17:16 |
Blog
Vivek Subbiah: Exhilarating discussions with my dear friend and amazing colleague Naveen Pemmaraju.
Vivek Subbiah, Executive Director at MDACC Cancer Network, shared on X/Twitter: “Exhilarating discussions with my…
Sep 16, 2023, 19:08 |
Insight
Vivek Subbiah: Super thrilled to deliver the keynote lecture on “Precision Oncology: Future is now” at the Binaytara Foundation.
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, recently shared…
Aug 31, 2023, 19:04 |
Insight
Naveen Pemmaraju: Ph2 CLIA with or without sorafenib for upfront AML therapy.
Naveen Pemmaraju, the Executive Director of Cancer Medicine at the MD Anderson Cancer Center, recently…
Aug 31, 2023, 18:52 |
Insight
Nitin Jain: Excited to share preclinical data with CRLF2 bispecific antibody for CRLF2-rearranged B-ALL.
Quoting Nitin Jain, the Director of Leukemia CAR-T Program at the MD Anderson Cancer Center:…
Jul 29, 2023, 18:50 |
Blog
All my appreciation for Naveen Pemmaraju for being a world leader in the field of BPDCN (yes 123 field !) and MPN - Nitin Jain
All my appreciation for Naveen Pemmaraju for being a world leader in the field of…
All:
25
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube